Opendata, web and dolomites

ImplantFreeSpine

World’s first complete motion-preservation 'Implant-less' surgical correction for Scoliosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ImplantFreeSpine project word cloud

Explore the words cloud of the ImplantFreeSpine project. It provides you a very rough idea of what is the project "ImplantFreeSpine" about.

innovative    directives    arthritis    permanent    alternative    selling    time    meeting    phases    huge    people    million    planning    revenues    chronic    deformities    quality    complexity    medical    complete    holds    commercialisation    preserves    invasive    solution    additional    rehabilitation    surgery    period    optimisation    12    prototype    undergo    model    2022    restricting    market    cure    business    capture    reported    grow    hypertension    months    scoliosis    lung    caused    marketing    post    life    population    conduct    hospitalisation    world    billion    42    procedure    physical    plan    rate    obstructive    spinal    spine    carry    annual    permanently    earn    severe    share    significantly    arrest    deformity    elimination    treatment    diabetes    correction          17    global    shorter    40    intend    care    disease    international    rigid    fusion    techniques    operative    introductory    compound    engage    mobility    surgical       safer    strategies    lifetime   

Project "ImplantFreeSpine" data sheet

The following table provides information about the project.

Coordinator
ATC GROUP LIMITED 

Organization address
address: UNIT 17 PERRYWOOD BUSINESS PARK HONEYCROCK LANE SALFORDS
city: REDHILL SURREY
postcode: RH1 5JQ
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.atcltd.co.uk/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ATC GROUP LIMITED UK (REDHILL SURREY) coordinator 50˙000.00

Map

 Project objective

Scoliosis affects 2-3% of the world population i.e. about 12 million people in the EU. 20,000 cases of severe scoliosis are reported each year in the EU but less than 3,000 cases ever undergo surgery due to cost and complexity of the surgery. Severe cases of scoliosis are treated by spinal fusion; a major surgical procedure that makes the spine permanently rigid restricting physical activities and permanent arrest of spinal growth. The impact of spinal deformity caused by scoliosis on the quality of life before and after surgery is huge compared with other chronic conditions such as arthritis, chronic obstructive lung disease, diabetes and hypertension. Due to the need for an alternative method for better correction of scoliosis deformities we have developed novel devices and a highly innovative care model involving a safer and significantly less invasive, complete cure which preserves spinal mobility and growth potential. Our solution will result in reduced cost of treatment by over 40% because of shorter hospitalisation, reduced operating time, elimination of additional procedures and lifetime care costs. Spine surgery currently holds a €10.2 billion global market share and is estimated to grow at a compound annual growth rate of 6.9% to reach €17.5 billion by 2022. We aim to capture a market share of 0.1% in 5 years post commercialisation of our project and earn compound revenues of €42.5 million by selling our devices over the same period. In Phase 1 of this project we intend to conduct detailed planning of the testing and design optimisation phases, carry out a market study plan, identify and engage international partners and develop a draft business plan for use upon commercialisation within a period of 6 months. In Phase 2 we will develop an advanced prototype meeting relevant EU and US Medical Devices Directives, demonstrate surgical techniques, rehabilitation strategies, and post-operative procedures and also conduct introductory marketing of our devices.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMPLANTFREESPINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMPLANTFREESPINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More